Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Statistics
Share Statistics
Akebia Therapeutics has 261.23M shares outstanding. The number of shares has increased by 24.64% in one year.
| Shares Outstanding | 261.23M |
| Shares Change (YoY) | 24.64% |
| Shares Change (QoQ) | 19.73% |
| Owned by Institutions (%) | 32.25% |
| Shares Floating | 250.51M |
| Failed to Deliver (FTD) Shares | 103.21K |
| FTD / Avg. Volume | 2.58% |
Short Selling Information
The latest short interest is 17.92M, so 6.86% of the outstanding shares have been sold short.
| Short Interest | 17.92M |
| Short % of Shares Out | 6.86% |
| Short % of Float | 6.92% |
| Short Ratio (days to cover) | 3.58 |
Valuation Ratios
The PE ratio is -5.77 and the forward PE ratio is 60.38. Akebia Therapeutics's PEG ratio is -0.32.
| PE Ratio | -5.77 |
| Forward PE | 60.38 |
| PS Ratio | 2.5 |
| Forward PS | 0.7 |
| PB Ratio | -8.15 |
| P/FCF Ratio | -9.85 |
| PEG Ratio | -0.32 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Akebia Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of -0.97.
| Current Ratio | 1.41 |
| Quick Ratio | 1.21 |
| Debt / Equity | -0.97 |
| Debt / EBITDA | -3.47 |
| Debt / FCF | -1.17 |
| Interest Coverage | -2.78 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $884.97K |
| Profits Per Employee | $-383.48K |
| Employee Count | 181 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 3.89 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 95.16% in the last 52 weeks. The beta is 0.86, so Akebia Therapeutics's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | 95.16% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 67.3 |
| Average Volume (20 Days) | 4M |
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.
| Revenue | 160.18M |
| Gross Profit | 97M |
| Operating Income | -50.47M |
| Net Income | -69.41M |
| EBITDA | -13.72M |
| EBIT | -51.23M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 51.87M in cash and 47.64M in debt, giving a net cash position of 4.23M.
| Cash & Cash Equivalents | 51.87M |
| Total Debt | 47.64M |
| Net Cash | 4.23M |
| Retained Earnings | -1.68B |
| Total Assets | 220.67M |
| Working Capital | 32.92M |
Cash Flow
In the last 12 months, operating cash flow was -40.66M and capital expenditures -33K, giving a free cash flow of -40.69M.
| Operating Cash Flow | -40.66M |
| Capital Expenditures | -33K |
| Free Cash Flow | -40.69M |
| FCF Per Share | -0.19 |
Margins
Gross margin is 60.56%, with operating and profit margins of -31.51% and -43.33%.
| Gross Margin | 60.56% |
| Operating Margin | -31.51% |
| Pretax Margin | -43.33% |
| Profit Margin | -43.33% |
| EBITDA Margin | -8.57% |
| EBIT Margin | -31.51% |
| FCF Margin | -25.4% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AKBA is $6.5, which is 168.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 168.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -9.33 |
| Piotroski F-Score | 3 |